Cerus (NASDAQ:CERS) Insider Richard Benjamin Sells 24,235 Shares

Cerus Corporation (NASDAQ:CERS) insider Richard Benjamin sold 24,235 shares of the stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $2.01, for a total value of $48,712.35. Following the sale, the insider directly owned 919,527 shares in the company, valued at $1,848,249.27. This trade represents a 2.57% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Cerus Stock Performance

Shares of CERS opened at $1.93 on Tuesday. Cerus Corporation has a twelve month low of $1.12 and a twelve month high of $2.96. The stock has a market cap of $370.89 million, a PE ratio of -24.13 and a beta of 1.51. The company has a quick ratio of 1.17, a current ratio of 1.73 and a debt-to-equity ratio of 0.62. The business’s 50-day moving average price is $2.31 and its 200-day moving average price is $1.86.

Cerus (NASDAQ:CERS) last released its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.01) EPS for the quarter, meeting analysts’ consensus estimates of ($0.01). The company had revenue of $64.58 million during the quarter, compared to analyst estimates of $59.31 million. Cerus had a negative net margin of 7.58% and a negative return on equity of 26.09%. On average, equities analysts forecast that Cerus Corporation will post -0.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on CERS. TD Cowen restated a “buy” rating on shares of Cerus in a research report on Monday, January 12th. Wall Street Zen downgraded Cerus from a “buy” rating to a “hold” rating in a research report on Saturday. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold”.

More Cerus News

Here are the key news stories impacting Cerus this week:

• Neutral Sentiment: Short-interest data flagged an apparent increase for the March 9 reporting period but shows 0 shares and reports a days-to-cover of 0.0 — the print looks incorrect or incomplete and should be treated as unreliable until exchanges update filings.
• Neutral Sentiment: Analysts overview: The Globe and Mail ran a piece discussing analysts’ views on Cerus alongside peers (Fennec). That coverage provides context but does not appear to contain new company-specific catalysts. Analysts Offer Insights on Healthcare Companies: Cerus (CERS) and Fennec Pharmaceuticals (FENC)
• Negative Sentiment: Insider selling: several insiders disclosed sales between Mar. 5–9 that reduce insider ownership by low-single-digit to mid-single-digit percentages. Notable filings: CEO William Mariner Greenman sold 78,187 shares (~$157k). COO Vivek Jayaraman sold 34,094 shares (~$68.5k). CFO Kevin D. Green sold 27,796 shares (~$55.9k). Director Richard J. Benjamin reported multiple sales (61,233; 40,426; 24,235 shares) at ~$2.06–$1.88 across Mar. 5–9. Insider Chrystal Jensen sold 30,845 shares (~$62k). Collectively, these are meaningful in signaling added supply and may weigh on sentiment even if sales were for personal/liquidity reasons. CEO filing: http://www.sec.gov/Archives/edgar/data/1020214/000137725826000004/xslF345X05/ownership.xml COO filing: http://www.sec.gov/Archives/edgar/data/1020214/000160545626000004/xslF345X05/ownership.xml Chrystal Jensen filing: http://www.sec.gov/Archives/edgar/data/1020214/000156425226000004/xslF345X05/ownership.xml Richard Benjamin filings: http://www.sec.gov/Archives/edgar/data/1020214/000129632226000004/xslF345X05/ownership.xml CFO filing: http://www.sec.gov/Archives/edgar/data/1020214/000145935126000005/xslF345X05/ownership.xml

Institutional Investors Weigh In On Cerus

A number of large investors have recently added to or reduced their stakes in CERS. Cubist Systematic Strategies LLC raised its position in Cerus by 152.4% during the first quarter. Cubist Systematic Strategies LLC now owns 104,101 shares of the biotechnology company’s stock valued at $145,000 after purchasing an additional 62,854 shares in the last quarter. AQR Capital Management LLC boosted its holdings in shares of Cerus by 291.6% in the 1st quarter. AQR Capital Management LLC now owns 1,429,062 shares of the biotechnology company’s stock worth $1,986,000 after purchasing an additional 1,064,133 shares in the last quarter. Millennium Management LLC increased its position in shares of Cerus by 12.0% during the 1st quarter. Millennium Management LLC now owns 3,222,327 shares of the biotechnology company’s stock valued at $4,479,000 after purchasing an additional 344,395 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Cerus during the 1st quarter valued at about $32,000. Finally, Savant Capital LLC raised its holdings in shares of Cerus by 339.6% during the 2nd quarter. Savant Capital LLC now owns 94,812 shares of the biotechnology company’s stock valued at $134,000 after buying an additional 73,244 shares in the last quarter. Hedge funds and other institutional investors own 78.37% of the company’s stock.

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.